Ponfibrate

This classification denotes an anti-lipidemic agent with the molecular formula C18H16Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ARR2L0V0A, chemically known as 12h-dibenzo(d,g)(1,3)dioxocin-6-carboxylic acid, 2,10-dichloro-12-methyl-, ethyl ester, trans- but generally known as ponfibrate, which bears US NIH Compound Identifier 68701. European Medicines Agency schedules Ponfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09979MIG. The term PONFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). PONFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ponfibrate under HS 29329970 and SITC 51569. As of Q4 2014, PONFIBRATE remains the US FDA Preferred Term for this commodity. Ponfibrate bears US NLM identifiers UMLS ID C2347628 and NCI Concept Code C72994. SMILES: Clc1cc2C(c3c(OC(Oc2cc1)C(=O)OCC)ccc(Cl)c3)C.